Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has updated the label for liso-cel (Breyanzi), removing the restriction that previously excluded patients with primary central nervous system lymphoma (PCNSL) from CAR T-cell therapy. This makes liso-cel the second CAR T product to receive this update, following axi-cel's label change in February 2026. The move broadens treatment access for a historically hard-to-treat patient population.
The FDA has approved a label update for lisocabtagene maraleucel (liso-cel/Breyanzi), removing the limitation of use that previously excluded patients with primary central nervous system lymphoma (PCNSL) from its large B-cell lymphoma (LBCL) indication. Liso-cel is now the second CAR T-cell therapy to receive this update, following axicabtagene ciloleucel (axi-cel/Yescarta), which had its PCNSL restriction lifted in February 2026.
The updated label covers a broad range of LBCL subtypes — including DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B — across multiple treatment settings: early relapse/refractory disease after first-line chemoimmunotherapy, transplant-ineligible patients, and those with relapsed/refractory disease after two or more prior lines of therapy.
Key Takeaways:
Why it matters: PCNSL is a rare and aggressive cancer with limited treatment options. Expanding CAR T-cell therapy access to this population could offer a meaningful new option for patients who previously had few alternatives after standard therapies failed.